BR9910583A - Aminotetralinas n-substituìdas como ligantes para o receptor de neuropeptìdeo y y5 úteis no tratamento de obesidade e outros distúrbios - Google Patents

Aminotetralinas n-substituìdas como ligantes para o receptor de neuropeptìdeo y y5 úteis no tratamento de obesidade e outros distúrbios

Info

Publication number: BR9910583A
Authority: BR; Brazil
Prior art keywords: binders; disorders; treatment; useful; obesity
Prior art date: 1998-04-29

Application number

BR9910583-7A

Other languages

English (en)

Portuguese (pt)

Inventor

Scott L Dax

Timothy Walter Loovenberg

James J Mcnally

Allen B Reitz

Mark Andrew Youngman

Original Assignee

Ortho Mcneil Pharm Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-04-29

Filing date

1999-04-12

Publication date

2001-01-09

1999-04-12 Application filed by Ortho Mcneil Pharm Inc filed Critical Ortho Mcneil Pharm Inc

2001-01-09 Publication of BR9910583A publication Critical patent/BR9910583A/pt

Links

208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 4
239000011230 binding agent Substances 0.000 title abstract 3
208000008589 Obesity Diseases 0.000 title abstract 2
235000020824 obesity Nutrition 0.000 title abstract 2
JRZGPXSSNPTNMA-UHFFFAOYSA-N 1,2,3,4-tetrahydronaphthalen-1-amine Chemical class C1=CC=C2C(N)CCCC2=C1 JRZGPXSSNPTNMA-UHFFFAOYSA-N 0.000 title 1
102000028517 Neuropeptide receptor Human genes 0.000 title 1
108070000018 Neuropeptide receptor Proteins 0.000 title 1
101710151321 Melanostatin Proteins 0.000 abstract 3
102400000064 Neuropeptide Y Human genes 0.000 abstract 3
208000035475 disorder Diseases 0.000 abstract 2
URPYMXQQVHTUDU-OFGSCBOVSA-N nucleopeptide y Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 URPYMXQQVHTUDU-OFGSCBOVSA-N 0.000 abstract 2
102000005962 receptors Human genes 0.000 abstract 2
108020003175 receptors Proteins 0.000 abstract 2
102100029549 Neuropeptide Y receptor type 5 Human genes 0.000 abstract 1
101710198055 Neuropeptide Y receptor type 5 Proteins 0.000 abstract 1
239000004480 active ingredient Substances 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
238000002360 preparation method Methods 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
- C07C311/18—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by nitrogen atoms, not being part of nitro or nitroso groups
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
- C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/37—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/14—Sulfones; Sulfoxides having sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
- C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/30—Hetero atoms other than halogen
- C07D333/34—Sulfur atoms

Landscapes

Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Cardiology (AREA)
Diabetes (AREA)
Pain & Pain Management (AREA)
Heart & Thoracic Surgery (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Hematology (AREA)
Endocrinology (AREA)
Obesity (AREA)
Reproductive Health (AREA)
Emergency Medicine (AREA)
Child & Adolescent Psychology (AREA)
Anesthesiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Peptides Or Proteins (AREA)
Furan Compounds (AREA)
Pyridine Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

BR9910583-7A 1998-04-29 1999-04-12 Aminotetralinas n-substituìdas como ligantes para o receptor de neuropeptìdeo y y5 úteis no tratamento de obesidade e outros distúrbios BR9910583A (pt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US8341598P	1998-04-29	1998-04-29
US09/290,651 US6140354A (en)	1998-04-29	1999-04-12	N-substituted aminotetralins as ligands for the neuropeptide Y Y5 receptor useful in the treatment of obesity and other disorders
PCT/US1999/007971 WO1999055667A1 (fr)	1998-04-29	1999-04-12	Aminotetralines n substituees, ligands du recepteur y y5 du neuropeptide servant au traitement de l'obesite et d'autres troubles

Publications (1)

Publication Number	Publication Date
BR9910583A true BR9910583A (pt)	2001-01-09

Family

ID=26769275

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BR9910583-7A BR9910583A (pt)	1998-04-29	1999-04-12	Aminotetralinas n-substituìdas como ligantes para o receptor de neuropeptìdeo y y5 úteis no tratamento de obesidade e outros distúrbios

Country Status (23)

Country	Link
US (1)	US6140354A (fr)
EP (1)	EP1076644B1 (fr)
JP (1)	JP2004503462A (fr)
CN (1)	CN1289475C (fr)
AT (1)	ATE269846T1 (fr)
AU (1)	AU759313B2 (fr)
BG (1)	BG64732B1 (fr)
BR (1)	BR9910583A (fr)
DE (1)	DE69918296T2 (fr)
DK (1)	DK1076644T3 (fr)
ES (1)	ES2223170T3 (fr)
HU (1)	HUP0102656A3 (fr)
ID (1)	ID26128A (fr)
IL (1)	IL139227A0 (fr)
NZ (1)	NZ507763A (fr)
PL (1)	PL194839B1 (fr)
PT (1)	PT1076644E (fr)
RO (1)	RO120542B1 (fr)
RU (1)	RU2219167C2 (fr)
TR (1)	TR200100137T2 (fr)
TW (1)	TW530043B (fr)
WO (1)	WO1999055667A1 (fr)
ZA (1)	ZA992951B (fr)

Families Citing this family (105)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2350714A1 (fr)	1998-11-10	2000-05-18	Merck & Co., Inc.	Spiro-indolines en tant qu'antagonistes du recepteur y5
CA2373035A1 (fr) *	1999-05-05	2000-11-16	Scott Dax	Ligands de recepteurs du neuropeptide y derives de 3a,4,5,9b-tetrahydro-1h-benz[e]indol-2-yl amine, utilises pour le traitement de l'obesite et d'autres etats pathologiques
US6841552B1 (en)	1999-05-05	2005-01-11	Ortho-Mcneil Pharmaceutical, Inc.	3a,4,5,9b-tetrahydro-1H-benz[e]indol-2-yl amine-derived neuropeptide Y receptors ligands useful in the treatment of obesity and other disorders
HUP0202143A3 (en) *	1999-07-28	2003-12-29	Ortho Mcneil Pharm Inc	Amine and amide derivatives as ligands for the neuropeptide y y5 receptor pharmaceutical compositions containing them and their use
US20050070499A1 (en) *	1999-11-08	2005-03-31	Pfizer Inc.	Compounds for the treatment of female sexual dysfunction
DK1249233T3 (da) *	1999-11-26	2008-11-17	Shionogi & Co	NPYY5-antagonister
GB0010757D0 (en)	2000-05-05	2000-06-28	Astrazeneca Ab	Chemical compounds
GB0011013D0 (en) *	2000-05-09	2000-06-28	Astrazeneca Ab	Chemical compounds
WO2002059310A2 (fr)	2000-12-12	2002-08-01	University Of Connecticut	Polynucleotides encoding cellular transporters and methods of use thereof
US20030082647A1 (en) *	2000-12-12	2003-05-01	Reenan Robert A.	Transporter protein
US6982251B2 (en) *	2000-12-20	2006-01-03	Schering Corporation	Substituted 2-azetidinones useful as hypocholesterolemic agents
ATE331512T1 (de)	2001-01-26	2006-07-15	Schering Corp	Verwendung azetidinone-substituierter verbindungen zur behandlung der sitosterolhämie
MEP27808A (en)	2001-01-26	2010-10-10	Schering Corp	Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
US7071181B2 (en)	2001-01-26	2006-07-04	Schering Corporation	Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
US7732451B2 (en)	2001-08-10	2010-06-08	Palatin Technologies, Inc.	Naphthalene-containing melanocortin receptor-specific small molecule
US7456184B2 (en)	2003-05-01	2008-11-25	Palatin Technologies Inc.	Melanocortin receptor-specific compounds
US7354923B2 (en) *	2001-08-10	2008-04-08	Palatin Technologies, Inc.	Piperazine melanocortin-specific compounds
US7655658B2 (en)	2001-08-10	2010-02-02	Palatin Technologies, Inc.	Thieno [2,3-D]pyrimidine-2,4-dione melanocortin-specific compounds
US7718802B2 (en)	2001-08-10	2010-05-18	Palatin Technologies, Inc.	Substituted melanocortin receptor-specific piperazine compounds
EP1425029A4 (fr) *	2001-08-10	2006-06-07	Palatin Technologies Inc	Peptidomimetiques de metallopeptides biologiquement actifs
GB0121709D0 (en) *	2001-09-07	2001-10-31	Imp College Innovations Ltd	Food inhibition agent
GB0121941D0 (en)	2001-09-11	2001-10-31	Astrazeneca Ab	Chemical compounds
US7053080B2 (en)	2001-09-21	2006-05-30	Schering Corporation	Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
JP2005504091A (ja)	2001-09-21	2005-02-10	シェーリング　コーポレイション	ステロール吸収阻害剤としてアゼチジノンを用いる黄色腫の処置
ES2320979T3 (es)	2001-09-24	2009-06-01	Imperial Innovations Limited	Pyy-36 para la reduccion o prevencion de la obesidad.
CA2403307A1 (fr)	2001-10-23	2003-04-23	Neurogen Corporation	Derives de l'imidazole 2-cyclohexyl-4-phenyl-1h substitue
DE10157673A1 (de) *	2001-11-24	2003-06-05	Merck Patent Gmbh	Verwendung von N-(Indolcarbonyl-)piperazinderivaten
WO2003053919A1 (fr) *	2001-12-12	2003-07-03	F. Hoffmann-La-Roche Ag	Derives substitues du cyclohexane
US8058233B2 (en) *	2002-01-10	2011-11-15	Oregon Health And Science University	Modification of feeding behavior using PYY and GLP-1
US6984647B2 (en)	2002-05-17	2006-01-10	Janssen Pharmaceutica N.V.	Aminotetralin-derived urea modulators of vanilloid VR1 receptor
US7105526B2 (en)	2002-06-28	2006-09-12	Banyu Pharmaceuticals Co., Ltd.	Benzimidazole derivatives
WO2004043457A1 (fr)	2002-11-06	2004-05-27	Schering Corporation	Inhibiteurs d'absorption de cholesterol pour le traitement de troubles auto-immuns
GB0300571D0 (en) *	2003-01-10	2003-02-12	Imp College Innovations Ltd	Modification of feeding behaviour
US7772188B2 (en)	2003-01-28	2010-08-10	Ironwood Pharmaceuticals, Inc.	Methods and compositions for the treatment of gastrointestinal disorders
US7459442B2 (en)	2003-03-07	2008-12-02	Schering Corporation	Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
CA2517571C (fr)	2003-03-07	2011-07-05	Schering Corporation	Azetidinones substituees , procedes pour leur preparation, formulations et utilisations de celles-ci
EP1606287B1 (fr)	2003-03-07	2013-10-02	Merck Sharp & Dohme Corp.	Composés d'azetidinone substitués, formulations et utilisations de ceux-ci pour traiter l'hypercholestérolémie
MXPA05009501A (es)	2003-03-07	2005-10-18	Schering Corp	Compuestos de azetidinona sustituidos, formulaciones y usos de los mismos para el tratamiento de hipercolesterolemia.
US7968548B2 (en)	2003-05-01	2011-06-28	Palatin Technologies, Inc.	Melanocortin receptor-specific piperazine compounds with diamine groups
US7727991B2 (en)	2003-05-01	2010-06-01	Palatin Technologies, Inc.	Substituted melanocortin receptor-specific single acyl piperazine compounds
US7727990B2 (en)	2003-05-01	2010-06-01	Palatin Technologies, Inc.	Melanocortin receptor-specific piperazine and keto-piperazine compounds
US20070099884A1 (en) *	2003-06-06	2007-05-03	Erondu Ngozi E	Combination therapy for the treatment of diabetes
US20060148721A1 (en) *	2003-06-06	2006-07-06	Erondu Ngozi E	Combination therapy for the treatment of dyslipidemia
EP1669350B1 (fr)	2003-09-22	2012-02-29	Msd K.K.	Derives de piperidine
US20080125403A1 (en)	2004-04-02	2008-05-29	Merck & Co., Inc.	Method of Treating Men with Metabolic and Anthropometric Disorders
US7709484B1 (en)	2004-04-19	2010-05-04	Palatin Technologies, Inc.	Substituted melanocortin receptor-specific piperazine compounds
WO2005114211A1 (fr) *	2004-05-21	2005-12-01	Bayer Healthcare Ag	Agents diagnostiques et therapeutiques destines a des maladies associees au recepteur couple aux proteines g nyp5 (npy5)
US8394765B2 (en) *	2004-11-01	2013-03-12	Amylin Pharmaceuticals Llc	Methods of treating obesity with two different anti-obesity agents
US20090156474A1 (en)	2004-11-01	2009-06-18	Amylin Pharmaceuticals, Inc.	Methods for treating obesity and obesity related diseases and disorders
US20090213731A1 (en) *	2005-04-15	2009-08-27	Regenertech Pty Limited	Use of neuropeptide y (npy) and agonists and antagonists thereof for tissue regeneration
US7737155B2 (en)	2005-05-17	2010-06-15	Schering Corporation	Nitrogen-containing heterocyclic compounds and methods of use thereof
EP1892241B1 (fr)	2005-05-30	2016-03-30	Msd K.K.	Nouveau derive de piperidine
GB0511986D0 (en) *	2005-06-13	2005-07-20	Imp College Innovations Ltd	Novel compounds and their effects on feeding behaviour
JPWO2007018248A1 (ja)	2005-08-10	2009-02-19	萬有製薬株式会社	ピリドン化合物
EP2330124B1 (fr)	2005-08-11	2015-02-25	Amylin Pharmaceuticals, LLC	Polypeptides hybrides ayant des propriétés sélectionnables
BRPI0614649A2 (pt)	2005-08-11	2011-04-12	Amylin Pharmaceuticals Inc	polipeptìdeos hìbridos com propriedades selecionáveis
JPWO2007024004A1 (ja)	2005-08-24	2009-03-05	萬有製薬株式会社	フェニルピリドン誘導体
US20090264426A1 (en)	2005-09-07	2009-10-22	Shunji Sakuraba	Bicyclic aromatic substituted pyridone derivative
WO2007041052A2 (fr)	2005-09-29	2007-04-12	Merck & Co., Inc.	Derives spiropiperidines acyles convenant comme modulateurs des recepteurs de la melanocortine-4
WO2007048027A2 (fr)	2005-10-21	2007-04-26	Novartis Ag	Combinaison de composes organiques
WO2007049798A1 (fr)	2005-10-27	2007-05-03	Banyu Pharmaceutical Co., Ltd.	Nouveau derive de benzoxathiine
CA2629018C (fr)	2005-11-10	2013-12-31	Banyu Pharmaceutical Co., Ltd.	Derive spiro aza-substitue
KR101441146B1 (ko) *	2006-04-28	2014-09-17	시오노기세야쿠 가부시키가이샤	Ｎｐｙｙ5 수용체 길항 작용을 갖는 아민 유도체
US7834017B2 (en)	2006-08-11	2010-11-16	Palatin Technologies, Inc.	Diamine-containing, tetra-substituted piperazine compounds having identical 1- and 4-substituents
WO2008039327A2 (fr)	2006-09-22	2008-04-03	Merck & Co., Inc.	Procédé de traitement utilisant des inhibiteurs de synthèse d'acide gras
AU2007301126A1 (en)	2006-09-28	2008-04-03	Banyu Pharmaceutical Co., Ltd.	Diaryl ketimine derivative
TWI428346B (zh) *	2006-12-13	2014-03-01	Imp Innovations Ltd	新穎化合物及其等對進食行為影響
EP2170930B3 (fr)	2007-06-04	2013-10-02	Synergy Pharmaceuticals Inc.	Agonistes de guanylase cyclase utiles pour le traitement de troubles gastro-intestinaux, d'inflammation, de cancer et d'autres troubles
US8969514B2 (en)	2007-06-04	2015-03-03	Synergy Pharmaceuticals, Inc.	Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
SA08290668B1 (ar)	2007-10-25	2012-02-12	شيونوجي آند كو.، ليمتد	مشتقات أمين لها نشاط مضاد لمستقبل npy y5 واستخداماتها
CN101939022A (zh) *	2007-11-14	2011-01-05	安米林药品公司	治疗肥胖以及肥胖相关疾病和病症的方法
JPWO2009110510A1 (ja)	2008-03-06	2011-07-14	Ｍｓｄ株式会社	アルキルアミノピリジン誘導体
US20110015198A1 (en)	2008-03-28	2011-01-20	Banyu Pharmaceutical Co., Inc.	Diarylmethylamide derivative having melanin-concentrating hormone receptor antagonism
JP2011522828A (ja)	2008-06-04	2011-08-04	シナジーファーマシューティカルズインコーポレイテッド	胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト
EP2301936A1 (fr)	2008-06-19	2011-03-30	Banyu Pharmaceutical Co., Ltd.	Dérivé de spirodiamine-diarylcétoxime
EP2321341B1 (fr)	2008-07-16	2017-02-22	Synergy Pharmaceuticals Inc.	Agonistes de guanylate cyclase utiles pour le traitement de troubles gastro-intestinaux, inflammatoires, cancéreux et autres
EP2319841A1 (fr)	2008-07-30	2011-05-11	Msd K.K.	Dérivé de cycloalkylamine à noyaux fusionnés à (5 chaînons)-(5 chaînons) ou (5 chaînons) (6 chaînons)
AU2009307884B2 (en)	2008-10-22	2014-07-31	Merck Sharp & Dohme Corp.	Novel cyclic benzimidazole derivatives useful anti-diabetic agents
CA2741644C (fr)	2008-10-30	2013-05-07	Merck Sharp & Dohme Corp.	Antagonistes d'isonicotinamide des recepteurs de l'orexine
CN102271509A (zh)	2008-10-31	2011-12-07	默沙东公司	用于抗糖尿病药的新型环苯并咪唑衍生物
EP2379547A1 (fr)	2008-12-16	2011-10-26	Schering Corporation	Dérivés de pyridopyrimidine et leurs procédés d'utilisation
US20110243940A1 (en)	2008-12-16	2011-10-06	Schering Corporation	Bicyclic pyranone derivatives and methods of use thereof
US8227618B2 (en)	2009-04-23	2012-07-24	Shionogi & Co., Ltd.	Amine-derivatives having NPY Y5 receptor antagonistic activity and the uses thereof
US8895596B2 (en)	2010-02-25	2014-11-25	Merck Sharp & Dohme Corp	Cyclic benzimidazole derivatives useful as anti-diabetic agents
US9616097B2 (en)	2010-09-15	2017-04-11	Synergy Pharmaceuticals, Inc.	Formulations of guanylate cyclase C agonists and methods of use
CN103476258B (zh)	2011-02-25	2017-04-26	默沙东公司	用作抗糖尿病药剂的新的环状氮杂苯并咪唑衍生物
AR088352A1 (es)	2011-10-19	2014-05-28	Merck Sharp & Dohme	Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina
US9227901B2 (en) *	2012-07-05	2016-01-05	Abbvie Inc.	Process for preparing bicyclic amine derivatives
US20140045746A1 (en)	2012-08-02	2014-02-13	Merck Sharp & Dohme Corp.	Antidiabetic tricyclic compounds
EP2958562B1 (fr)	2013-02-22	2025-09-10	Merck Sharp & Dohme LLC	Composés bicycliques antidiabétiques
EP2970119B1 (fr)	2013-03-14	2021-11-03	Merck Sharp & Dohme Corp.	Nouveaux dérivés d'indole utiles en tant qu'agents antidiabétiques
CA2905435A1 (fr)	2013-03-15	2014-09-25	Synergy Pharmaceuticals Inc.	Compositions utiles pour le traitement de troubles gastro-intestinaux
US9708367B2 (en)	2013-03-15	2017-07-18	Synergy Pharmaceuticals, Inc.	Agonists of guanylate cyclase and their uses
RS65632B1 (sr)	2013-06-05	2024-07-31	Bausch Health Ireland Ltd	Ultra-prečišćeni agonisti guanilat-ciklaze c, postupak njihove pripreme i upotrebe
WO2015051496A1 (fr)	2013-10-08	2015-04-16	Merck Sharp & Dohme Corp.	Composés tricycliques antidiabétiques
CN113121450A (zh)	2014-08-29	2021-07-16	Tes制药有限责任公司	α-氨基-β-羧基粘康酸半醛脱羧酶抑制剂
US20180134667A1 (en)	2016-10-14	2018-05-17	TES Pharma S.r.I.	Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
WO2018106518A1 (fr)	2016-12-06	2018-06-14	Merck Sharp & Dohme Corp.	Composés hétérocycliques antidiabétiques
WO2018118670A1 (fr)	2016-12-20	2018-06-28	Merck Sharp & Dohme Corp.	Composés de spirochromane antidiabétiques
US11439608B2 (en)	2017-09-25	2022-09-13	Qun Lu	Roles of modulators of intersectin-CDC42 signaling in Alzheimer's disease
IL283182B2 (en)	2018-11-20	2025-10-01	Tes Pharma S R L	Alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase inhibitors
WO2020167706A1 (fr)	2019-02-13	2020-08-20	Merck Sharp & Dohme Corp.	Agonistes du récepteur de l'orexine 5-alkyl-pyrrolidine
US12331018B2 (en)	2019-02-13	2025-06-17	Merck Sharp & Dohme Llc	Pyrrolidine orexin receptor agonists
WO2021026047A1 (fr)	2019-08-08	2021-02-11	Merck Sharp & Dohme Corp.	Agonistes du récepteur de l'orexine de type pyrrolidine et pipéridine hétéroaryle
CA3189908A1 (fr)	2020-08-18	2022-02-24	Stephane L. Bogen	Agonistes du recepteur de l'orexine de type bicycloheptane pyrrolidine

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3718317A1 (de) *	1986-12-10	1988-06-16	Bayer Ag	Substituierte basische 2-aminotetraline
JP2785879B2 (ja) *	1989-05-31	1998-08-13	ジ・アップジョン・カンパニー	治療学的に有用な２―アミノテトラリン誘導体
FR2701480B1 (fr) *	1993-02-15	1995-05-24	Sanofi Elf	Composés à groupe sulfamoyle et amidino, leur procédé de préparation et les compositions pharmaceutiques les contenant.
AU7692996A (en) *	1995-12-01	1997-06-27	Ciba-Geigy Ag	Receptor antagonists
WO1997019682A1 (fr) *	1995-12-01	1997-06-05	Synaptic Pharmaceutical Corporation	Derives aryle sulfonamide et sulfamide, et leurs utilisations

1999
- 1999-04-12 AT AT99918500T patent/ATE269846T1/de not_active IP Right Cessation
- 1999-04-12 ID IDW20002189A patent/ID26128A/id unknown
- 1999-04-12 EP EP99918500A patent/EP1076644B1/fr not_active Expired - Lifetime
- 1999-04-12 WO PCT/US1999/007971 patent/WO1999055667A1/fr not_active Ceased
- 1999-04-12 HU HU0102656A patent/HUP0102656A3/hu unknown
- 1999-04-12 AU AU36400/99A patent/AU759313B2/en not_active Ceased
- 1999-04-12 JP JP2000545828A patent/JP2004503462A/ja active Pending
- 1999-04-12 RU RU2000127036/04A patent/RU2219167C2/ru not_active IP Right Cessation
- 1999-04-12 DK DK99918500T patent/DK1076644T3/da active
- 1999-04-12 CN CNB998053937A patent/CN1289475C/zh not_active Expired - Fee Related
- 1999-04-12 PL PL343771A patent/PL194839B1/pl unknown
- 1999-04-12 ES ES99918500T patent/ES2223170T3/es not_active Expired - Lifetime
- 1999-04-12 IL IL13922799A patent/IL139227A0/xx not_active IP Right Cessation
- 1999-04-12 US US09/290,651 patent/US6140354A/en not_active Expired - Lifetime
- 1999-04-12 TR TR2001/00137T patent/TR200100137T2/xx unknown
- 1999-04-12 PT PT99918500T patent/PT1076644E/pt unknown
- 1999-04-12 RO ROA200001058A patent/RO120542B1/ro unknown
- 1999-04-12 BR BR9910583-7A patent/BR9910583A/pt not_active Application Discontinuation
- 1999-04-12 NZ NZ507763A patent/NZ507763A/xx unknown
- 1999-04-12 DE DE69918296T patent/DE69918296T2/de not_active Expired - Fee Related
- 1999-04-26 ZA ZA9902951A patent/ZA992951B/xx unknown
- 1999-05-26 TW TW088106980A patent/TW530043B/zh not_active IP Right Cessation
2000
- 2000-10-23 BG BG104877A patent/BG64732B1/bg unknown

Also Published As

Publication number	Publication date
IL139227A0 (en)	2001-11-25
PL343771A1 (en)	2001-09-10
AU3640099A (en)	1999-11-16
JP2004503462A (ja)	2004-02-05
BG104877A (en)	2001-06-29
PL194839B1 (pl)	2007-07-31
HUP0102656A2 (hu)	2002-03-28
ATE269846T1 (de)	2004-07-15
NZ507763A (en)	2003-06-30
RU2219167C2 (ru)	2003-12-20
TW530043B (en)	2003-05-01
RO120542B1 (ro)	2006-03-30
BG64732B1 (bg)	2006-01-31
HUP0102656A3 (en)	2002-12-28
DE69918296T2 (de)	2005-08-04
ID26128A (id)	2000-11-23
TR200100137T2 (tr)	2001-05-21
AU759313B2 (en)	2003-04-10
EP1076644B1 (fr)	2004-06-23
CN1289475C (zh)	2006-12-13
US6140354A (en)	2000-10-31
DE69918296D1 (de)	2004-07-29
CN1298386A (zh)	2001-06-06
DK1076644T3 (da)	2004-08-30
ES2223170T3 (es)	2005-02-16
PT1076644E (pt)	2004-10-29
ZA992951B (en)	2000-10-26
WO1999055667A1 (fr)	1999-11-04
EP1076644A1 (fr)	2001-02-21

Publication	Publication Date	Title
BR9910583A (pt)	2001-01-09	Aminotetralinas n-substituìdas como ligantes para o receptor de neuropeptìdeo y y5 úteis no tratamento de obesidade e outros distúrbios
BR9914360A (pt)	2001-11-20	N-aralquilaminotetralinas como ligandos para oreceptor neuropeptìdeo yy5
WO2001062737A3 (fr)	2002-03-14	Derives d'amino pyrazole utilises dans le traitement de l'obesite et d'autres troubles
BR0012804A (pt)	2002-08-06	Derivados de amina e amida como ligandos para o receptor de neuropeptìdeo y y5 útil no tratamento da obesidade e outros distúrbios
EE200300403A (et)	2003-12-15	N-asendatud mittearomaatne heterotsükliline ühend, seda sisaldav ravimkompositsioon ning ühendi kasutamine ravimina
BR0115965A (pt)	2003-10-28	Composições farmacêuticas para a liberação oral de agentes farmacologicamente ativos
BRPI0007487B8 (pt)	2021-05-25	difenil-uréias substituídas com w-carbóxi-arilas como inibidores de raf cinase
BRPI0108395B8 (pt)	2021-05-25	derivados de pirrolopirimidinona, processos de preparação e uso
BR0112756A (pt)	2003-06-24	Composto, composição farmacêutica, métodos para o tratamento de doenças mediadas por prostaglandina, de congestão nasal, asma alérgica, e rinite alérgica, e, uso de um composto
BR0209580A (pt)	2004-06-22	Derivados de ciclohexan-1, 4 diamina substituìdos
BR0206955A (pt)	2004-03-09	Ligantes de receptores de canabinóides
BR9910180A (pt)	2001-01-09	Composição farmacêutica, processos para o tratamento de uma condição associada com a transmissão reduzida de nicotina, para identificação de um modulador positivo de um agonista receptor nicotìnico e para identificação de um composto, composto, e, uso de um modulador positivo de um agonista receptor nicotìnico
MXPA04000707A (es)	2004-04-20	Nuevos antagonistas del receptor y5 del neuropeptido y referencia cruzada a solicitudes relacionadas.
BRPI0113162B8 (pt)	2021-05-25	compostos ariloxialquilaminas nao-imidazólicos e composição farmacêutica compreendendo os referidos compostos
UY26130A1 (es)	2000-12-29	Compuestos para tratar la obesidad
BRPI0416752A (pt)	2007-02-27	composição farmacêutica, uso de um ou mais compostos, método para a prevenção ou tratamento de distúrbios, compostos, e, processo para a preparação de uma composição farmacêutica
BR0314797A (pt)	2005-07-26	Derivados da pirimidineamida e o uso dos mesmos
BR9812492A (pt)	2000-09-26	Composto, uso do mesmo, formulação farmacêutica, e, processos para o tratamento de uma doença cardiovascular, para o tratamento de uma vasoconstrição, e para a preparação de compostos
NO20020282L (no)	2002-03-21	Nytt difenyl-piperidinderivat
BR0113590A (pt)	2003-07-22	7-oxo-piridopirimidinas
BR9916575A (pt)	2001-09-18	Composição farmacêutica de liberação controlada com mesilato de tilidina como substância-ativa
BR0008302A (pt)	2002-08-27	Uso de um derivado de benzaldeìdo, derivado de benzaldeìdo, composição farmacêutica, e, processo para a fabricação da mesma
MY133512A (en)	2007-11-30	Non-steroidal il-5 inhibitors, processes and intermediates for their preparation and pharmaceutical compositions comprising said inhibitors
BR9809234A (pt)	2000-06-27	Composto, composição farmacêutica, uso de um composto, processos para tratar ou prevenir doenças do sistema endocrinológico, para fabricar um medicamento, para preparar um composto e um conjunto, conjunto, e, uso do mesmo.
BRPI0410623A (pt)	2006-06-20	composto, processo para preparação de um composto, composição farmacêutica, e, utilização de um composto

Legal Events

Date	Code	Title	Description
2008-01-02	B07A	Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
2008-01-02	B15K	Others concerning applications: alteration of classification	Free format text: ALTERADA DE INT.CL.8: C07C 311/05, C07C 311/18, C07C 311/20, C07C 311/22, C07C 311/29, C07C 311/37, C07C 311/41, C07C 317/14, C07D 213/16,C07D 213/38, C07D 233/54, C07D 233/64, C07D 307/52, C07D 333/20, C07D 333/34, A61K 31/18, A61K 31/341, A61K 31/381, A61K 31/4164, A61K 31/44, A61K 31/4406, A61K 31/4409, A61K 31/4418, A61P 3/04, A61P 9/00, A61P 9/04, A61P 9/12, A61P 15/00, A61P 25/00, A61P 25/04, A61P 25/06, A61P 25/08, A61P 25/20, A61P 25/22, A61P 25/24, A61P 25/28, A61P 43/00 Ipc: C07C 311/05 (2007.10), C07C 311/18 (2007.10), C07C
2008-05-20	B09B	Patent application refused [chapter 9.2 patent gazette]	Free format text: INDEFIRO O PRESENTE PEDIDO DE PATENTE DE ACORDO COM ART. 8O DA LPI.

Date

Code

Title

Description

2008-01-02

B07A

Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]

2008-01-02

B15K

Others concerning applications: alteration of classification

Free format text: ALTERADA DE INT.CL.8: C07C 311/05, C07C 311/18, C07C 311/20, C07C 311/22, C07C 311/29, C07C 311/37, C07C 311/41, C07C 317/14, C07D 213/16,C07D 213/38, C07D 233/54, C07D 233/64, C07D 307/52, C07D 333/20, C07D 333/34, A61K 31/18, A61K 31/341, A61K 31/381, A61K 31/4164, A61K 31/44, A61K 31/4406, A61K 31/4409, A61K 31/4418, A61P 3/04, A61P 9/00, A61P 9/04, A61P 9/12, A61P 15/00, A61P 25/00, A61P 25/04, A61P 25/06, A61P 25/08, A61P 25/20, A61P 25/22, A61P 25/24, A61P 25/28, A61P 43/00

Ipc: C07C 311/05 (2007.10), C07C 311/18 (2007.10), C07C

2008-05-20

B09B

Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PRESENTE PEDIDO DE PATENTE DE ACORDO COM ART. 8O DA LPI.